CluePoints Founder Named One of Life Sciences Most Inspiring People by PharmaVOICE
PharmaVoice: Congratulations to CluePoints founder, Dr. Marc Buyse, on being recognized in this year’s PharmaVOICE 100! With thousands of nominations to consider, Marc, the “Savvy Statistician”, was chosen for his innovative and entrepreneurial spirit, applying statistical research to real-world problems and demonstrating the value of statistics in medical research.
CluePoints Chief Commercial Officer Named in PharmaVOICE Top 100 Most Inspiring People in the Life Sciences Industry
Cambridge, MA – CluePoints, a leading provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, has today announced that its Chief Commercial Officer, Patrick Hughes, has been honored by PharmaVOICE as one of the 100 most inspiring people in the life sciences industry. Patrick was recognized for his pioneering work in risk-based monitoring (RBM) and dedication to challenging the industry’s traditional practices and processes when it comes to data analysis in clinical trials.
CluePoints Wins ENTENTE Life Science Investment Forum Award
The Entente award program, which is part of the European Venture Summit, acknowledged CluePoints for its Central Statistical Monitoring (CSM) solution that employs unique statistical algorithms to determine the quality, accuracy and integrity of clinical trial data. The win represents the second industry award that CluePoints has secured this month after the company’s risk-based monitoring solution was also recognized by the Scrip Awards.
CluePoints Wins Scrip Award for Best Technological Development in Clinical Trials
CluePoints was honoured with the award for the ‘Best Technological Development in Clinical Trials’ at the 2014 Scrip Awards held at The Lancaster Hotel, London on 3 December. The award, sponsored by the MCT Congress, recognizes ‘CluePoints in the Cloud’ as the ultimate quality oversight and risk-based monitoring (RBM) application developed to determine the quality and integrity of clinical trials data.